IA
ZYNE

IFP Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

IFP Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23
Closed -$7 – 3608
2023
Q2 		$7 Buy
+23
New +$8 ﹤0.01% 3431
2019
Q1 		$3K Buy
500
+60
+14% +$292 ﹤0.01% 2042
2018
Q4 		$1K Hold
440
– – ﹤0.01% 3430
2018
Q3 		$4K Hold
440
– – ﹤0.01% 3348
2018
Q2 		$4K Sell
440
-150
-25% -$1.54K ﹤0.01% 3411
2018
Q1 		$7K Hold
590
– – ﹤0.01% 3028
2017
Q4 		$7K Sell
590
-100
-14% -$1.15K ﹤0.01% 3074
2017
Q3 		$6K Sell
690
-415
-38% -$4.39K ﹤0.01% 3340
2017
Q2 		$19K Buy
1,105
+565
+105% +$11.2K ﹤0.01% 2627
2017
Q1 		$11K Sell
540
-3,360
-86% -$66.8K ﹤0.01% 2875
2016
Q4 		$61K Buy
3,900
+2,000
+105% +$26.9K ﹤0.01% 1760
2016
Q3 		$25K Buy
1,900
+1,300
+217% +$12.3K ﹤0.01% 2279
2016
Q2 		$4K Buy
600
+100
+20% +$837 ﹤0.01% 3283
2016
Q1 		$3K Buy
+500
New +$4.03K ﹤0.01% 2036

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

IFP Advisors's ZYNE Position: Q3 2023 in Review

IFP Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 23 shares — an estimated $7 sold.

IFP Advisors first reported a position in ZYNE in Q1 2016 and held it in 14 quarters. The position peaked at $61K in Q4 2016. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

  • IFP Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
  • IFP Advisors sold 23 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $7.
  • IFP Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2016 and held it in 14 quarters.
  • IFP Advisors's Zynerba Pharmaceuticals, Inc position peaked at $61K in Q4 2016.
  • 43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on IFP Advisors's 13F filing for Q3 2023, filed 12 Oct 2023.